Xpovio mulligan in endometrial cancer misses primary endpoint while Karyopharm presses on in myelofibrosis on July 31, 2026 Jakafi Maintenance therapy Malignant neoplasm of endometrium PFS primary endpoint Primary Myelofibrosis ruxolitinib SENTRY trial SVR35 Symptoms score United States Food and Drug Administration Xpovio +